我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

血糖波动与糖尿病大血管并发症的相关性

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第2期
页码:
173-177
栏目:
临床研究
出版日期:
2018-02-15

文章信息/Info

Title:
The relationship between glucose fluctuation and macrovascular complications in type 2 diabetes
作者:
段建芳; 王艳妮; 金凤钟; 彭 燕; 徐先桔; 王晓明; 苏 慧
（第四军医大学西京医院老年病科，陕西 西安 710032）
Author(s):
DUAN Jian-fang;  WANG Yan-ni;  JIN Feng-zhong;  PENG Yan;  XU Xian-ju;  WANG Xiao-ming;  SU Hui
(Department of Geriatrics, Xijing Hospital, the Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
糖尿病; 2型; 血糖波动; 大血管并发症
Keywords:
diabetes mellitus;  type 2;  glucose fluctuation;  macrovascular complications
分类号:
R587.1
DOI:
-
文献标识码:
A
摘要:
目的 分析糖尿病大血管并发症与血糖波动之间的关系。方法 选取2型糖尿病（T2DM）患者作为研究对象，根据是否伴有大血管并发症分为大血管并发症组（66例）和无大血管并发症组（76例）。记录研究对象的一般临床资料、实验室指标及动态血糖监测（CGM）资料。结果 ①大血管并发症组的年龄、DM病程、高血糖时间百分比、高血糖AUC、MBG、低血糖发生率、2hPPG、SDBG、MAGE、LAGE均显著大于或高于无大血管并发症组（P<0.05或P<0.01）。而两组间性别比例、吸烟史、高血压史、降糖药物使用情况、血脂、肝功、FPG及HbA1c等指标均无统计学差异。②逐步Logistic回归分析显示大血管并发症与年龄、MAGE呈独立正相关。③Spearman相关性分析显示大血管并发症与年龄、DM病程、高血糖时间百分比、高血糖AUC、低血糖发生率、MBG、2hPPG、SDBG、MAGE、LAGE均呈正相关。结论 血糖波动指标MAGE与2型糖尿病患者大血管并发症相关。
Abstract:
AIM To investigate the relationship between glucose fluctuation and macrovascular complications in type 2 diabetes mellitus (T2DM). METHODS Patients with T2DM were included in the study. The patients were divided into macrovascular complications group (66 cases) and non-macrovascular complications group (76 cases). General clinical data and laboratory indexes of the subjects were recorded. Continue glucose monitoring (CGM) was performed in both groups. RESULTS Age, duration of DM, the percentage of hyperglycemia, the area under curve (AUC) above 11.1 mmol/L, MBG, incidence of hypoglycemia, SDBG, MAGE and LAGE were higher in the macrovascular complications group than in the non-macrovascular complications group (all P<0.05 or P<0.01). There was no significant difference in the ratio of gender, smoker, hypertension, types of antidiabetic drugs, serum lipids, alanine aminotransferase, aspartate aminotransferase, FPG and HbA1c between the two groups. Stepwise logistic regression analyses indicated that macrovascular complications were positively related with age and MAGE independently. Macrovascular complications were positively related with age, duration of DM, percentage of hyperglycemia, area under curve (AUC) above 11.1 mmol/L, incidence of hypoglycemia, MBG, 2hPPG, SDBG, MAGE and LAGE using Spearman’s correlation analysis. CONCLUSION Macrovascular complications were positively related with MAGE in type 2 diabetes mellitus.

参考文献/References

[1]The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus[J].N Engl J Med,1993,329(14):977-986.

[2]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33).UK Prospective Diabetes Study(UKPDS)Group[J].Lancet,1998,352(9131):837-853.

[3]Quagliaro L,Piconi L,Assaloni R,et al.Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation[J].Diabetes,2003,52(11):2795-2804.

[4]Piconi L,Quagliaro L,Da RR,et al.Intermittent high glucose enhances ICAM-1,VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose)polymerase[J].J Thromb Haemost,2004,2(8):1453-1459.

[5]Muggeo M,Zoppini G,Bonora E,et al.Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients:the Verona Diabetes Study[J].Diabetes Care,2000,23(1):45-50.

[6]Cavalot F,Petrelli A,Traversa M,et al.Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus,particularly in women: lessons from the San Luigi Gonzaga Diabetes Study[J].J Clin Endocrinol Metab,2006,91(3):813-819.

[7]Esposito K,Giugliano D,Nappo F,et al.Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus[J].Circulation,2004,110(2):214-219.

[8]Su G,Mi S,Tao H,et al.Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes[J].Cardiovasc Diabetol,2011,10:19.

[9]Borg R,Kuenen JC,Carstensen B,et al.HbA1(c)and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose(ADAG)study[J].Diabetologia,2011,54(1):69-72.

[10]Probstfield JL,Hirsch I O’Brien K,et al.Design of FLAT-SUGAR:Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes[J].Diabetes Care,2015,38(8):1558-1566.

[11]FLAT-SUGAR Trial Investigators.Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk[J].Diabetes Care,2016,39(6):973-981.

[12]Goto A,Arah OA,Goto M,et al.Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis[J].BMJ,2013,347:f4533.

[13]Smith-Palmer J,Brandle M,Trevisan R,et al.Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes[J].Diabetes Res Clin Pract,2014,105(3):273-284.

[14]Bergenstal RM.Glycemic Variability and Diabetes Complications:Does It Matter? Simply Put, There Are Better Glycemic Markers![J].Diabetes Care,2015,38(8):1615-1621.

[15]Kosiborod M,Inzucchi SE,Krumholz HM,et al.Glucometrics in patients hospitalized with acute myocardial infarction:defining the optimal outcomes-based measure of risk[J].Circulation,2008,117(8):1018-1027.

[16]Zoungas S,Patel A,Chalmers J,et al.Severe hypoglycemia and risks of vascular events and death[J].N Engl J Med,2010,363(15):1410-1418.

[17]Qu Y,Jacober SJ,Zhang Q,et al.Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data[J].Diabetes Technol Ther,2012,14(11):1008-1012.

[18]Buse JB,Bergenstal RM,Glass LC,et al.Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes:a randomized, controlled trial[J].Ann Intern Med,2011,154(2):103-112.

[19]Riddle MC,Aronson R,Home P,et al.Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin:a 24-week, randomized, placebo-controlled comparison (GetGoal-L)[J].Diabetes Care,2013,36(9):2489-2496.

[20]Diamant M,Nauck MA,Shaginian R,et al.Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes[J].Diabetes Care,2014,37(10):2763-2773.

[21]Garg S,Zisser H,Schwartz S,et al.Improvement in glycemic excursions with a transcutaneous,real-time continuous glucose sensor: a randomized controlled trial[J].Diabetes Care,2006,29(1):44-50.

备注/Memo

备注/Memo:
收稿日期：2017-05-20.基金项目：国家自然科学基金项目资助（31371151） 通讯作者：苏慧，副主任医师，主要从事老年心血管疾病研究 Email：huisu2014@163.com 作者简介：段建芳，硕士生 Email：86464529@qq.com
更新日期/Last Update: 1900-01-01